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Abstract 
A comorbidity is defined as the presence of at least one additional health condition co-occurring 
with a primary health condition.  Decision analytic models in healthcare depict the typical clinical 
pathway of patients in general clinical practice and frequently include health states defined to 
represent comorbidities such as sequelae or adverse events.  Health state utility values (HSUV) are 
often not available for these and analysts generally estimate these.  This article provides a summary 
of the methodological literature on estimating methods frequently used together with worked 
examples. 
 
The three main methods used (minimum, multiplicative and additive) can produce a wide range in 
the values estimated.  In general, the minimum method overestimates observed HSUVs and the 
magnitude of error tends to increase as the observed values decrease.  Conversely, the additive and 
multiplicative methods generally underestimate observed values and the magnitude of the errors is 
generally greater for the additive method.  HSUVs estimated using the multiplicative method tend to 
decrease for lower HSUVs and the largest errors are in observed HSUVs greater than 0.6. 
 
Differences in estimated values can produce substantial differences in the resulting incremental cost 
effectiveness ratio.  Based on the current evidence, the multiplicative method is advocated but 
additional research is required to determine appropriate methods when estimating values for 
additional comorbidities. 
 
Key points for decision makers  
 
x Ideally all HSUVs should be obtained directly from people with the conditions of interest and 
should only be estimated when the required evidence is not available. 
x HSUVs for comorbidities should be estimated using the multiplicative method and the 
required multipliers should be obtained used age-adjusted condition-specific evidence 
where possible. 
x It is recommended that a range of sensitivity analyses are performed to determine if results 
from the decision analytic model are robust to changes in HSUVs, preferably using a 
threshold analysis. 
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1. Introduction 
Decision analytic models in health care are designed to represent the typical clinical pathway 
followed by patients in general clinical practice.  They can range from simple decision trees involving 
just two health states (e.g. alive and dead) to more complex models with numerous discrete health 
states representing the primary condition of interest, and additional health states representing 
associated clinical events or sequelea, prevalent comorbidities, and treatment related adverse 
events.   
 
One example where multiple health states may be required is when exploring the potential benefits 
of weight loss interventions in obese populations.  Obesity is associated with an increased risk of 
cardiovascular disease, type 2 diabetes, respiratory conditions, gallstones and some cancers.  
Pharmaceutical interventions prescribed for weight loss can produce adverse side effects such as 
diarrhoea or an increase in blood pressure levels, while surgical interventions such as gastric bypass 
are associated with infections, internal bleeding, and deep vein thrombosis.  A decision analytic 
model assessing the benefits of a pharmaceutical intervention would potentially include at least 
some of these comorbidities.  While the probability of the simultaneous presence of all the 
comorbidities presented in Figure 1 is extremely small, it is reasonable to expect that an obese 
subject with diabetes may experience a heart attack or be diagnosed with obstructive sleep apnea at 
some point. 
 
In addition to the independent decrement on HSUVs associated with changes in body mass index, to 
model the full effects of weight changes, analysts constructing such a model would require the 
HSUVs for health states representing combinations of the health conditions.  While clinical studies 
provide evidence on the short-term health related quality of life (HRQoL) benefits of weight-loss, 
due to relatively low incidence rates for comorbidities, they may not provide the corresponding 
evidence from, for example, patients who have diabetes and experience a stroke. 
 
This article provides a synopsis of the literature describing methodological research on methods 
used to estimate health state utility values (HSUVs) for comorbidities.  A comorbidity is defined as 
the presence of at least one additional health condition co-occurring with a primary health 
condition.  Recommendations and worked examples are provided where possible. 
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2. Preferred methods used to estimate HSUVs for comorbidities 
Ideally HSUVs are obtained directly from people with the particular combination of conditions of 
interest.  While there is now a substantial volume of evidence providing HSUVs for people with 
single health conditions, the evidence base for cohorts with comorbidities is more limited.  In theory 
it is possible to design a study that would include every possible combination and permutation of 
health conditions.  In reality, the associated resource implications are prohibitive, and analysts 
frequently need to utilise more limited evidence.   
 
When HSUVs from individuals with comorbidities are not available, analysts may make use of mean 
HSUVs obtained from subgroups with individual conditions to estimate a mean HSUV for the 
comorbidity.  For example, considering the obesity model, estimating a HSUV for diabetes and the 
comorbidity heart attack, analysts would use evidence obtained from people with diabetes (but no 
history of a heart attack) and evidence obtained from people with a history of a heart attack (but no 
history of diabetes) to estimate the required evidence.  These data could be sourced from clinical 
studies that exclude patients with a history of specific conditions, or those taking non study drugs, 
although care should be taken to ensure check the exact exclusion criteria used to eliminate the risk 
of double counting.  The technical question is how to use the evidence that is known from the 
subgroups with the single conditions, to estimate the potential effect on utility when the two 
conditions occur simultaneously.   
Diarrhoea 
Bowel cancer 
Gall bladder 
disease 
Hypertension 
Cardiovascular 
disease 
Type 2 
diabetes 
Death 
Obese (with no 
comorbidity) 
Figure 1  Health states in a decision analytic model assessing the potential benefits of a 
pharmaceutical intervention for weight loss 
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Traditional estimation techniques include: the minimum method (assumes no additional decrement 
associated with comorbidity) 
[1,2,3,4]
 and the additive (applies the combined absolute disutility from 
the two single conditions on the baseline 
[1,2,3,4,5]
, thus has a constant effect) and multiplicative 
method (multiplies the two utilities from the single conditions, thus has a relative effect) 
[1,2,3,4,5,6]
.  
There is evidence providing a statistical linear regression model that can be used to predict mean 
HSUVs (UK, EQ-5D-3L) for two comorbidities using mean HSUVs from subgroups with single 
conditions 
[2,3]
.  The research used EQ-5D evidence collected in the Health Survey for England and 
the function was obtained by regressing the mean EQ-5D from subgroups with just one particular 
health condition onto the mean EQ-5D from subgroups (n = 96) with two corresponding 
comorbidities (i.e. evidence from the subgroup who had condition A (but not condition B), and 
evidence from the subgroup who had condition B (but not condition A) were used to predict the EQ-
5D score for the subgroup who had both condition A and condition B) 
[3]
. While the results are 
promising, as the model has not been validated in external data, it cannot currently be 
recommended and details are provided in Table 1 for completeness only.  A worked example 
comparing results using the alternative methods is provided below.   
 
Worked example   
Using EQ-5D data and self-reported responses of history of particular health conditions collected in 
the Health Survey for England, evidence from a subgroup with diabetes (but no history of a heart 
attack) and evidence from a subgroup with a history of a heart attack (but no history of diabetes) are 
used to estimate a mean HSUV for the comorbidity diabetes and heart attack 
[7]
.  The observed mean 
EQ-5D score for the combined comorbidity diabetes and heart attack is 0.5188 whilst the mean 
scores for diabetes and heart attack are 0.7304 and 0.6492 respectively.  The corresponding mean 
score for people who do not have these conditions (i.e. the condition specific baseline evidence) is 
0.9864 for the absence of both conditions,  0.9361 for the absence of diabetes and 0.9378 for the 
absence of heart attack).   
 
Using the alternative methods to estimate values for the health state diabetes and heart attack 
produces HSUVs ranging from 0.4921 when using the additive method, to 0.6492 when using the 
minimum method (see Table 2 for calculations).  The multiplicative method and statistical regression 
model produce estimates closer to the observed value (0.5188) at 0.5328 and 0.5310 respectively. 
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Table 1  Methods used to estimate HSUVs for comorbidities 
Method Function  
Additive  Assumes a constant absolute decrement (relative 
to the baseline) 
Minimum  Assumes no additional decement over that 
observed for the condition with the lowest HSUV 
Multiplicative 
 
 Assumes a constant relative decrement (relative 
to the baseline) 
Statistical 
regression 
model 
[3] 
 
 
 
 
 
D = -0.1007821; E1 = 0.0439155; E2 = 0.1545328; E3 = 1.143514## 
Incorporates terms representing the additive, 
multiplicative and minimum methods 
##
 The coefficients provided in this table are suitable for UK EQ-5D 3L evidence only.  Key: U ʹ utility; superscripts ʹ Add, Min, Mult, LM, represent the methods used (Add ʹ 
additive; Min ʹ minimum; Mult ʹ multiplicative; LM ʹ linear model); subscripts ʹ A, B, AB, nA, nB, nAnB, represent the presence (or absence) of conditions (A ʹ condition A 
(but not condtion B); B ʹ condition B (but not condtion A); AB ʹ both condition A and condition B; nA ʹ not condition A; nB ʹ not condition B; nAnB ʹ neither condition A 
nor condition B).  NB. These methods are only appropriate when combining evidence obtained using the same preference-based measure. 
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Table 2 Observed and estimated mean HSUVs for the comorbidity diabetes and heart attack 
Condition 
Observed mean 
HSUV 
Age-matched mean HSUV from people without 
the condition(s) of interest
# 
Diabetes & heart attack  0.5188 No history of diabetes or heart attack = 0.9864 
Just diabetes 0.7304 No history of diabetes = 0.9361 
Just heart attack 0.6492 No history of heart attack = 0.9378 
Method used 
Estimated mean 
HSUV 
Calculations 
Additive 0.4921 ൌ ͲǤͻͺ͸Ͷ െ ൫ሺͲǤͻ͵͸ͳ െ ͲǤ͹͵ͲͶሻ൅ ሺͲǤͻ͵͹ͺ െ ͲǤ͸Ͷͻʹሻ൯ 
Minimum 0.6492 ൌ ሺͲǤͻͺ͸Ͷǡ ͲǤ͹͵ͲͶǡ ͲǤ͸Ͷͻʹሻ 
Multiplicative 0.5328 ൌ ͲǤͻͺ͸Ͷ ൈ ሺͲǤ͹͵ͲͶ ൊ ͲǤͻ͵͸ͳሻൈ ሺͲǤ͸Ͷͻʹ ൊ ͲǤͻ͵͹ͺሻ 
Statistical regression 
model
 
0.5310 ൌ െͲǤͳͲͲ͹ͺʹͳ ൅ ͲǤͲͶ͵ͻͳͷͷ ൈ ൫ሺͲǤͻ͵͸ͳ െͲǤ͹͵ͲͶሻǡ ሺͲǤͻ͵͹ͺ െ ͲǤ͸Ͷͻʹሻ൯ ൅ ͲǤͳͷͶͷ͵ʹͺ ൈ൫ሺͲǤͻ͵͸ͳ െ ͲǤ͹͵ͲͶሻǡ ሺͲǤͻ͵͹ͺ െͲǤ͸Ͷͻʹሻ൯ ൅ ͳǤͳͶ͵ͷͳͶ ൈሺͲǤͻ͵͸ͳǡ ͲǤͻ͵͹ͺሻ ൈ ሺͲǤ͹͵ͲͶ ൊ ͲǤͻ͵͸ͳሻ ൈሺͲǤ͸Ͷͻʹ ൊ ͲǤͻ͵͹ͺሻ  
#
 If condition specific age-matched evidence is not available, evidence from the general population may be 
used 
 
The three traditional techniques can often produce substantially different scores and the estimated 
HSUVs may be noticeably different from the observed HSUVs.  Using data from the Health Survey for 
England, Figure 2 provides the observed and corresponding estimated EQ-5D scores for a variety of 
comorbidities 
[3]
.  The observed HSUVs are ordered by decreasing score and plotted with the 
corresponding calculated value.  It can be seen that the minimum method overestimates all the 
observed scores and the magnitude of error in the estimated scores tends to increase as the 
observed scores decrease.  Conversely, the additive and multiplicative methods generally 
underestimate the observed scores and the magnitude of error in the estimated scores is generally 
greater for the additive method 
[8]
.  There is a tendency for errors in the estimated values to 
decrease for lower HSUVs when using the multiplicative method (largest errors in values > 0.6). 
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Figure 2 Observed and estimated mean EQ-5D HSUVs for cohorts with two comorbidities 
 
Source: adapted from Ara & Brazier, 2012
[3]
 
 
3. Literature describing methods used to estimate HSUVs for comorbidities 
A literature review conducted to inform a NICE Technical Support Document (searches: 1950 to 
February 2012) identified just 11 articles exploring the accuracy of methods used to estimate HSUVs 
for comorbidities 
[9]
.  As the existing empirical evidence provided conflicting results and conclusions, 
the main objective of the paper was to gain an understanding of potential reasons for differences in 
reported results and conclusions. 
 
The authors reported the results and conclusions in the studies were influenced by the methods 
compared (the majority of studies compared just two methods), the range of HSUVs estimated (the 
observed mean HSUVs for the comorbidities in the majority of studies covered a truncated range at 
the higher end of the index), and the evidence used within the calculations (the accuracy of the 
methods increased when age- and condition-adjusted data were used to estimate the multipliers 
and decrements).  In addition, summary statistics such as mean errors in the estimated HSUVs were 
often used to assess the performance of the methods.  These statistics can conceal systematic errors 
as is seen in the HSUVs estimated using the minimum method in Figure 2. 
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While the authors of the review identified plausible explanations for the contradictory results and 
conclusions reported in the literature, they recommended that additional methodological research 
was required in this area.  Based on the evidence reviewed, they concluded that when assessed 
across the full preference-based indices, the multiplicative method appeared to estimate the most 
accurate HSUVs.  They recommended the multiplicative method using age and condition specific 
evidence to estimate the multipliers when possible.  However, this recommendation was informed 
by research exploring the methods when used to estimate HSUVs for just two concurrent health 
conditions. 
 
4. Uncertainty in HSUVs for comorbidities 
When using estimated HSUVs in decision analytic models, it is particularly important to demonstrate 
the potential effect on the incremental cost-effectiveness ratio (ICER) when using alternative values.  
One approach might be to present ICERs generated using the alternative estimation methods as 
sensitivity analyses (retaining the multiplicative method in the base case).  An alternative might be 
to present results using arbitrary adjustments to the estimated mean values (e.g. plus or minus 
20%).  However, the most appropriate approach would be to perform a threshold analysis, whereby 
the ICER threshold is used to determine the range of possible values the estimated HSUV would have 
to be within for the results to be considered cost-effective.  
 
5. Issues and areas for future research 
5.1 Estimating HSUVs for more than two concurrent comorbidities 
The vast majority of published research on this topic presents results comparing the accuracy of 
methods when used to estimate HSUVs for just two concurrent health conditions.  In practice, many 
people, and particularly the elderly, have more than two comorbidities.  It is not possible to use the 
published regression models for more than two concurrent conditions as there is no term for 
additional comorbidities.  Of the three traditional techniques, the minimum method has been shown 
to underestimate the effects on HSUVs when used for two concurrent comorbidities and it is 
reasonable to assume that it may produce larger errors if used to estimate a HSUV for three or more 
concurrent comorbidities.  It is not known which of the additive and multiplicative methods would 
produce the most accurate estimates for more than two concurrent comorbidities.  When adding 
the effects of additional comorbidities, the additive method will quickly produce HSUVs below the 
bottom range of the index while the multiplicative method will quickly tend towards zero.  Given the 
findings from the research on two comorbidities, it seems likely that the multiplicative method 
might be the preferred method, but this is an area where additional research is justified.   
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5.2 Health dimensions affected by the condition(s) 
The methods referenced above utilise the effect observed on the overall preference-based index 
irrespective of the characteristics of the health condition.  It is possible that the combined effect of 
two conditions which both affect physical dimensions such as pain and self-care (e.g. rheumatoid 
arthritis and cancer) may differ substantially from the combined effect of two conditions which both 
affect mental health dimensions (e.g. schizophrenia and depression).  This notion could be explored 
by using the proportions of responses to the health dimensions for the individual conditions to 
predict the proportion of responses to the health dimensions for the comorbidity, rather than the 
mean HSUVs. 
 
5.3 Negative health state utility values 
Although rare, there are occasions when the mean cohort HSUV is below zero.  This can be 
problematic when using individual level data in a discrete event simulation but can also generate 
implausible values when estimating HSUVs for comorbidities.  For example, when using the 
multiplicative method, combining an even number of negative HSUVs will produce a positive HSUV.  
Similarly, combining three of more large decrements using the additive method could produce a 
HSUV  below the bottom limit of the preference-based index.  It is unclear which of the methods are 
best suited to estimating HSUVs in these cases.   
 
 
6. Summary 
The differences in estimated HSUVs obtained using the alternative methods could potentially bias 
results generated from decision analytic models and thus have implications for policy decisions 
informed by these analyses.  If policy makers are not empowered to gauge the magnitude or 
direction of potential differences in ICERs generated using the alternative methods this may 
undermine their confidence in results if the ICER is sensitive to changes in HSUVs.  This is an area 
where more work is needed as all of the methods currently used have limitations, particularly at the 
individual level.  Whichever method is used there is a risk of double-counting the decrements on 
health if the evidence used for the single health conditions includes patients with comorbidities.  
Consequently it is important to review the inclusion and exclusion criteria used in the original studies 
and to adhere to transparent reporting standards when describing the evidence used. 
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The current recommendation is to estimate HSUVs using the multiplicative method, with the caveat 
that caution is needed when estimating HSUVs for more than two concurrent comorbidities, or 
when at least one HSUV is below zero.  A range of sensitivity analyses should be performed (e.g. 
threshold analysis) to explore the effect on the ICER when varying the HSUVs used within the model. 
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